Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

Preetesh Jain, Hagop Kantarjian, Keyur Patel, Stefan Faderl, Guillermo Garcia-Manero, Ohad Benjamini, Gautam Borthakur, Naveen Pemmaraju, Tapan Kadia, Naval Daver, Aziz Nazha, Raja Luthra, Sherry Pierce, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1337-1344
Number of pages8
JournalLeukemia and Lymphoma
Volume55
Issue number6
DOIs
StatePublished - Jun 2014
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Karyotype
Recurrence
Clone Cells
Mutation

Keywords

  • AML
  • Minimal residual disease
  • MRD
  • NPM1 mutations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Jain, P., Kantarjian, H., Patel, K., Faderl, S., Garcia-Manero, G., Benjamini, O., ... Ravandi, F. (2014). Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma, 55(6), 1337-1344. https://doi.org/10.3109/10428194.2013.840776

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. / Jain, Preetesh; Kantarjian, Hagop; Patel, Keyur; Faderl, Stefan; Garcia-Manero, Guillermo; Benjamini, Ohad; Borthakur, Gautam; Pemmaraju, Naveen; Kadia, Tapan; Daver, Naval; Nazha, Aziz; Luthra, Raja; Pierce, Sherry; Cortes, Jorge; Ravandi, Farhad.

In: Leukemia and Lymphoma, Vol. 55, No. 6, 06.2014, p. 1337-1344.

Research output: Contribution to journalArticle

Jain, P, Kantarjian, H, Patel, K, Faderl, S, Garcia-Manero, G, Benjamini, O, Borthakur, G, Pemmaraju, N, Kadia, T, Daver, N, Nazha, A, Luthra, R, Pierce, S, Cortes, J & Ravandi, F 2014, 'Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse', Leukemia and Lymphoma, vol. 55, no. 6, pp. 1337-1344. https://doi.org/10.3109/10428194.2013.840776
Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma. 2014 Jun;55(6):1337-1344. https://doi.org/10.3109/10428194.2013.840776
Jain, Preetesh ; Kantarjian, Hagop ; Patel, Keyur ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Benjamini, Ohad ; Borthakur, Gautam ; Pemmaraju, Naveen ; Kadia, Tapan ; Daver, Naval ; Nazha, Aziz ; Luthra, Raja ; Pierce, Sherry ; Cortes, Jorge ; Ravandi, Farhad. / Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 6. pp. 1337-1344.
@article{3ec0fad1e374452aa6587b54dd186c63,
title = "Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse",
abstract = "Patients with newly diagnosed AML (n = 360) including 137 (38{\%}) with normal karyotype (NK) were evaluated. Overall, 60 (16.6{\%}) patients, including 46 of the 137 (33.5{\%}) NK patients, had NPM1 mutation at baseline. Thirty-nine patients (30 NK) had available NPM1 status at the time of complete remission (CR) and all (100{\%}) were negative for mutated NPM1. Among the patients with mutated NPM1 at baseline, 10/39 overall (25{\%}) and 7/30 NK (23{\%}) patients relapsed. NPM1 status was available for eight patients (six with NK) at the time of relapse. Among them, 7/8 overall (87{\%}) and 5/6 NK (83{\%}) patients had mutated NPM1, while 1/8 overall (12{\%}) and 1/6 NK (16{\%}) patients remained NPM1 wild type. Among the 300 patients (including 91 with NK) with wild type NPM1 at diagnosis, none acquired a mutated NPM1 clone, either at CR or at relapse. We conclude that mutated NPM1 is a stable and reliable prognostic marker in AML and can be used to assess MRD.",
keywords = "AML, Minimal residual disease, MRD, NPM1 mutations",
author = "Preetesh Jain and Hagop Kantarjian and Keyur Patel and Stefan Faderl and Guillermo Garcia-Manero and Ohad Benjamini and Gautam Borthakur and Naveen Pemmaraju and Tapan Kadia and Naval Daver and Aziz Nazha and Raja Luthra and Sherry Pierce and Jorge Cortes and Farhad Ravandi",
year = "2014",
month = "6",
doi = "10.3109/10428194.2013.840776",
language = "English (US)",
volume = "55",
pages = "1337--1344",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

AU - Jain, Preetesh

AU - Kantarjian, Hagop

AU - Patel, Keyur

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Benjamini, Ohad

AU - Borthakur, Gautam

AU - Pemmaraju, Naveen

AU - Kadia, Tapan

AU - Daver, Naval

AU - Nazha, Aziz

AU - Luthra, Raja

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2014/6

Y1 - 2014/6

N2 - Patients with newly diagnosed AML (n = 360) including 137 (38%) with normal karyotype (NK) were evaluated. Overall, 60 (16.6%) patients, including 46 of the 137 (33.5%) NK patients, had NPM1 mutation at baseline. Thirty-nine patients (30 NK) had available NPM1 status at the time of complete remission (CR) and all (100%) were negative for mutated NPM1. Among the patients with mutated NPM1 at baseline, 10/39 overall (25%) and 7/30 NK (23%) patients relapsed. NPM1 status was available for eight patients (six with NK) at the time of relapse. Among them, 7/8 overall (87%) and 5/6 NK (83%) patients had mutated NPM1, while 1/8 overall (12%) and 1/6 NK (16%) patients remained NPM1 wild type. Among the 300 patients (including 91 with NK) with wild type NPM1 at diagnosis, none acquired a mutated NPM1 clone, either at CR or at relapse. We conclude that mutated NPM1 is a stable and reliable prognostic marker in AML and can be used to assess MRD.

AB - Patients with newly diagnosed AML (n = 360) including 137 (38%) with normal karyotype (NK) were evaluated. Overall, 60 (16.6%) patients, including 46 of the 137 (33.5%) NK patients, had NPM1 mutation at baseline. Thirty-nine patients (30 NK) had available NPM1 status at the time of complete remission (CR) and all (100%) were negative for mutated NPM1. Among the patients with mutated NPM1 at baseline, 10/39 overall (25%) and 7/30 NK (23%) patients relapsed. NPM1 status was available for eight patients (six with NK) at the time of relapse. Among them, 7/8 overall (87%) and 5/6 NK (83%) patients had mutated NPM1, while 1/8 overall (12%) and 1/6 NK (16%) patients remained NPM1 wild type. Among the 300 patients (including 91 with NK) with wild type NPM1 at diagnosis, none acquired a mutated NPM1 clone, either at CR or at relapse. We conclude that mutated NPM1 is a stable and reliable prognostic marker in AML and can be used to assess MRD.

KW - AML

KW - Minimal residual disease

KW - MRD

KW - NPM1 mutations

UR - http://www.scopus.com/inward/record.url?scp=84901335895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901335895&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.840776

DO - 10.3109/10428194.2013.840776

M3 - Article

C2 - 24004182

AN - SCOPUS:84901335895

VL - 55

SP - 1337

EP - 1344

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -